GW274150

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

Arthritis, RheumatoidAsthmaMigraineMigraine Disorders

Phase 1

Study With GW274150 In Patients With Mild Asthma

CompletedNCT00273013

GlaxoSmithKlineAsthma

Start: 2004-11-15End: 2005-10-28Updated: 2017-10-18

Phase 2

Use Of GW274150 In The Prophylactic Treatment Of Migraine

CompletedNCT00242866

GlaxoSmithKlineMigraine Disorders

Start: 2005-10-31End: 2007-09-30Updated: 2016-05-09

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

CompletedNCT00319137

GlaxoSmithKlineMigraine, Migraine Disorders

Start: 2005-12-31Target: 126Updated: 2012-06-04

Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)

CompletedNCT00370435

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2005-08-31End: 2005-09-30Updated: 2017-05-30

A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.

CompletedNCT00379990

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2006-01-31End: 2007-12-31Updated: 2012-07-02

Related Papers

Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma.

2007-08-23112 citations